Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.
Actively Recruiting
Researchers are studying the use of FDA-approved targeted therapies for patients with advanced cancer whose tumors have specific genomic changes that may respond to these drugs. This non-randomized Phase 2 trial aims to understand the safety and effects of these targeted anticancer treatments in real-world clinical practice. The study catalogs molecular profiling tests used by doctors and helps develop ideas for further clinical trials. Participants receive one of several targeted drug treatments based on their tumors genetic profile. These include drugs such as sunitinib, trastuzumab with pertuzumab, vemurafenib with cobimetinib, olaparib, nivolumab with ipilimumab, abemaciclib, talazoparib, atezolizumab with talazoparib, tucatinib with trastuzumab, futibatinib, dabrafenib with trametinib, or fam-trastuzumab deruxtecan-nxki. Dosage, frequency, and duration follow approved labeling. Each drug is matched to specific genomic variants identified in the tumor. Participants must be at least 12 years old and have advanced cancer that is no longer benefiting from standard treatment or for which no approved therapy is available. They undergo genomic testing to identify actionable tumor variants and receive treatment accordingly. Researchers assess tumor response at 16 weeks and monitor overall survival for up to 3 years. Safety and treatment effects are observed throughout the study, which lasts until 2028, with results shared publicly as they become available.